Barclays Maintains Underweight on DexCom, Lowers Price Target to $67

Benzinga Newsdesk www.benzinga.com Negative 91.4%

Neg 91.4% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the price target from $72 to $67.